Damora Therapeutics/$DMRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Damora Therapeutics
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Ticker
$DMRA
Sector
Primary listing
Employees
7
Headquarters
Website
DMRA Metrics
BasicAdvanced
$1.5bn
-
-$153.95
1.57
-
Price and volume
Market cap
$1.5bn
Beta
1.57
52-week high
$38.33
52-week low
$2.45
Average daily volume
281k
Financial strength
Current ratio
12.978
Quick ratio
12.884
Long term debt to equity
0.022
Total debt to equity
0.028
Profitability
EBITDA (TTM)
-36.54
Effective tax rate (TTM)
-0.02%
Management effectiveness
Return on assets (TTM)
-16.46%
Return on equity (TTM)
-163.80%
Valuation
Price to book
-0.23
Price to tangible book (TTM)
-0.23
Price to free cash flow (TTM)
-5.168
Free cash flow yield (TTM)
-19.35%
Free cash flow per share (TTM)
-4.935
Growth
Earnings per share change (TTM)
730.95%
3-year earnings per share growth (CAGR)
36.43%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Damora Therapeutics stock?
Damora Therapeutics (DMRA) has a market cap of $1.5B as of April 29, 2026.
What is the P/E ratio for Damora Therapeutics stock?
The price to earnings (P/E) ratio for Damora Therapeutics (DMRA) stock is 0 as of April 29, 2026.
Does Damora Therapeutics stock pay dividends?
No, Damora Therapeutics (DMRA) stock does not pay dividends to its shareholders as of April 29, 2026.
When is the next Damora Therapeutics dividend payment date?
Damora Therapeutics (DMRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Damora Therapeutics?
Damora Therapeutics (DMRA) has a beta rating of 1.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.